With the further understanding of the molecular mechanism of HER2-positive breast cancer, a series of HER2-targeted drugs have been developed, including trastuzumab, pertuzumab, lapatinib, neratinib, T-DM1, and pyrotinib have been approved for the treatment of HER2-positive breast cancer. The gene discussed is ERBB2; the disease is breast carcinoma.